dm+d
Unassigned
New Medicines
Multiple sclerosis (MS)
Information
New molecular entity
Biogen
Biogen
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Oct 16: Biogen discontinues development of MT-1303 after reviewing their priorities [1].
Category
An immunosupressant, selective sphingosine-1-phosphate1 (S1P1) receptor modulator [2]
In England and Wales the annual incidence and prevalence of MS is 3.5-6.6 and 100-120 per 100,000, respectively.
Multiple sclerosis (MS)
Oral